Nature Communications (Jun 2023)

Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer

  • Thanh Nguyen,
  • Dhivya Sridaran,
  • Surbhi Chouhan,
  • Cody Weimholt,
  • Audrey Wilson,
  • Jingqin Luo,
  • Tiandao Li,
  • John Koomen,
  • Bin Fang,
  • Nagireddy Putluri,
  • Arun Sreekumar,
  • Felix Y. Feng,
  • Kiran Mahajan,
  • Nupam P. Mahajan

DOI
https://doi.org/10.1038/s41467-023-38887-7
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 19

Abstract

Read online

Abstract The testicular androgen biosynthesis is well understood, however, how cancer cells gauge dwindling androgen to dexterously initiate its de novo synthesis remained elusive. We uncover dual-phosphorylated form of sterol regulatory element-binding protein 1 (SREBF1), pY673/951-SREBF1 that acts as an androgen sensor, and dissociates from androgen receptor (AR) in androgen deficient environment, followed by nuclear translocation. SREBF1 recruits KAT2A/GCN5 to deposit epigenetic marks, histone H2A Lys130-acetylation (H2A-K130ac) in SREBF1, reigniting de novo lipogenesis & steroidogenesis. Androgen prevents SREBF1 nuclear translocation, promoting T cell exhaustion. Nuclear SREBF1 and H2A-K130ac levels are significantly increased and directly correlated with late-stage prostate cancer, reversal of which sensitizes castration-resistant prostate cancer (CRPC) to androgen synthesis inhibitor, Abiraterone. Further, we identify a distinct CRPC lipid signature resembling lipid profile of prostate cancer in African American (AA) men. Overall, pY-SREBF1/H2A-K130ac signaling explains cancer sex bias and reveal synchronous inhibition of KAT2A and Tyr-kinases as an effective therapeutic strategy.